Delta4 Featured in the Finanz und Wirtschaft (FuW)
Delta4 is honored to have been featured in a recent article by Finanz und Wirtschaft, highlighting our pioneering work in AI-driven drug repurposing. The article sheds light on how our AI-powered platform, Hyper-C, identifies novel therapeutic uses for existing drugs, offering hope for more efficient and effective treatment strategies for a range of complex conditions. […]
Delta4, in preparation for the first clinical study, focused on FSGS
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and genetic background. FSGS patients often progress to end-stage renal disease requiring dialysis and/or kidney transplantation, adding a significant socioeconomic burden to the individual burden of patients. There are approximately 140.000 patients with FSGS worldwide, qualifying […]
Press Release – June 2020
Delta4 Announces Results Achieved with Drug Discovery Platform Vienna, Europe (June 2, 2020) – Delta4, a biotech company using its proven digital drug discovery platform to identify new indications for approved drugs, today announced recent results achieved in two drug discovery and development programs. In its lead program, which aims at developing a therapy for […]